Evidence map›Paper›PMID 24371721›Full record

ArticleFEBS open bio2013

Quantitation of fibroblast activation protein (FAP)-specific protease activity in mouse, baboon and human fluids and organs.

Fiona M Keane, Tsun-Wen Yao, Stefanie Seelk, Margaret G Gall, Sumaiya Chowdhury, Sarah E Poplawski, Jack H Lai, Youhua Li, Wengen Wu, Penny Farrell and 16 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in FEBS open bio, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 131 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. [Positron emission tomography in sarcomas].Radiologie (Heidelberg, Germany) · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Diagnostic Efficacy of FAPI-PET/CT Versus [Diagnostics (Basel, Switzerland) · 2026
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 7 institutions in 3 countries.

Fiona M KeaneCentenary Institute, Camperdown, NSW, Australia ; Sydney Medical School, University of Sydney, NSW, Australia.
Tsun-Wen YaoCentenary Institute, Camperdown, NSW, Australia ; Sydney Medical School, University of Sydney, NSW, Australia.
Stefanie SeelkCentenary Institute, Camperdown, NSW, Australia.
Margaret G GallCentenary Institute, Camperdown, NSW, Australia ; Sydney Medical School, University of Sydney, NSW, Australia.
Sumaiya ChowdhuryCentenary Institute, Camperdown, NSW, Australia ; Sydney Medical School, University of Sydney, NSW, Australia.
Sarah E PoplawskiSackler School of Biomedical Sciences, Tufts University School of Medicine, Boston, MA, USA.
Jack H LaiSackler School of Biomedical Sciences, Tufts University School of Medicine, Boston, MA, USA.
Youhua LiSackler School of Biomedical Sciences, Tufts University School of Medicine, Boston, MA, USA.
Wengen WuSackler School of Biomedical Sciences, Tufts University School of Medicine, Boston, MA, USA.
Penny FarrellDepartment of Renal Medicine, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
Ana Julia Vieira de RibeiroCentenary Institute, Camperdown, NSW, Australia ; Sydney Medical School, University of Sydney, NSW, Australia.
Brenna OsborneCentenary Institute, Camperdown, NSW, Australia ; Sydney Medical School, University of Sydney, NSW, Australia.
Denise M T YuCentenary Institute, Camperdown, NSW, Australia ; Sydney Medical School, University of Sydney, NSW, Australia.
Devanshi SethCentenary Institute, Camperdown, NSW, Australia ; Drug Health Services, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
Khairunnessa RahmanDrug Health Services, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
Paul HaberSydney Medical School, University of Sydney, NSW, Australia ; Drug Health Services, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
A Kemal TopalogluPediatric Endocrinology, Faculty of Medicine, Cukurova University, Adana, Turkey.
Chuanmin WangSydney Medical School, University of Sydney, NSW, Australia ; Collaborative Transplantation Research Group, Bosch Institute, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
Sally ThomsonSydney Medical School, University of Sydney, NSW, Australia ; Department of Renal Medicine, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
Annemarie HennessyDepartment of Renal Medicine, Royal Prince Alfred Hospital, Camperdown, NSW, Australia ; School of Medicine, University of Western Sydney, NSW, Australia.
John PrinsMater Medical Research Institute, University of Queensland, and Department of Endocrinology, Princess Alexandra Hospital, Brisbane, QLD, Australia.
Stephen M TwiggSydney Medical School, University of Sydney, NSW, Australia ; Department of Endocrinology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
Susan V McLennanSydney Medical School, University of Sydney, NSW, Australia ; Department of Endocrinology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
Geoffrey W McCaughanCentenary Institute, Camperdown, NSW, Australia ; Sydney Medical School, University of Sydney, NSW, Australia.
William W BachovchinSackler School of Biomedical Sciences, Tufts University School of Medicine, Boston, MA, USA.
Mark D GorrellCentenary Institute, Camperdown, NSW, Australia ; Sydney Medical School, University of Sydney, NSW, Australia.
Centenary Institute · AUThe University of Sydney · AURoyal Prince Alfred Hospital · AUTufts University · USCukurova University · TRPrincess Alexandra Hospital · AUWestern Sydney University · AU

Funding

Using FAP to Selectively Target Epithelial CancersR01CA163930 · NCI · TUFTS UNIVERSITY BOSTON · PI BACHOVCHIN, WILLIAM W · 2012 to 2016
$1.7M
A FAP-Activated Proteasome Inhibitor for Killing Solid TumorsR42CA156930 · NCI · ARISAPH PHARMACEUTICALS, INC. · PI BACHOVCHIN, WILLIAM W, JONES, BARRY · 2014 to 2015
$1.1M
NCI NIH HHS R01 CA163930NCI NIH HHS R42 CA156930
6 · The paper itself

Abstract

The protease fibroblast activation protein (FAP) is a specific marker of activated mesenchymal cells in tumour stroma and fibrotic liver. A specific, reliable FAP enzyme assay has been lacking. FAP's unique and restricted cleavage of the post proline bond was exploited to generate a new specific substrate to quantify FAP enzyme activity. This sensitive assay detected no FAP activity in any tissue or fluid of FAP gene knockout mice, thus confirming assay specificity. Circulating FAP activity was ∼20- and 1.3-fold less in baboon than in mouse and human plasma, respectively. Serum and plasma contained comparable FAP activity. In mice, the highest levels of FAP activity were in uterus, pancreas, submaxillary gland and skin, whereas the lowest levels were in brain, prostate, leukocytes and testis. Baboon organs high in FAP activity included skin, epididymis, bladder, colon, adipose tissue, nerve and tongue. FAP activity was greatly elevated in tumours and associated lymph nodes and in fungal-infected skin of unhealthy baboons. FAP activity was 14- to 18-fold greater in cirrhotic than in non-diseased human liver, and circulating FAP activity was almost doubled in alcoholic cirrhosis. Parallel DPP4 measurements concorded with the literature, except for the novel finding of high DPP4 activity in bile. The new FAP enzyme assay is the first to be thoroughly characterised and shows that FAP activity is measurable in most organs and at high levels in some. This new assay is a robust tool for specific quantitation of FAP enzyme activity in both preclinical and clinical samples, particularly liver fibrosis.

Indexed as

ALD, alcoholic liver diseaseAMC, amino-4-methylcoumarinBiomarkerDipeptidyl peptidaseDMSO, dimethyl sulfoxideDPP4, dipeptidyl peptidase 4EDTA, ethylene diamine tetra acetic acidFAP, fibroblast activation protein-αFibroblastFibrosisgko, gene knock outHCV, hepatitis C virushet, heterozygousLDS, lithium dodecyl sulphateLiver diseaseLN, lymph nodemAb, monoclonal antibodyND, non-diseasedPBC, primary biliary cirrhosisPBMC, peripheral blood mononuclear cellsPBS, phosphate-buffered salinePEP, prolyl endopeptidaseProtease activityProtease substratesPVDF, polyvinylidene fluorideSTLV, simian T-cell lymphotrophic viruswt, wild typeyrs, years

Identifiers

PMID24371721
PMCPMC3871272
OpenAlexW2170211456

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.